Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. The company is headquartered in Houston, Texas and currently employs 1 full-time employees. The company went IPO on 2004-08-20. The firm is focused on exploring strategic alternatives, including, but not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. Separately, the Company is evaluating several potential in-licensing opportunities in obesity, oncology and virology.
How did TCRT's recent EPS compare to expectations?
The most recent EPS for Alaunos Therapeutics Inc is $, expectations of $.
How did Alaunos Therapeutics Inc TCRT's revenue perform in the last quarter?
Alaunos Therapeutics Inc revenue for the last quarter is $
What is the revenue estimate for Alaunos Therapeutics Inc?
According to of Wall street analyst, the revenue estimate of Alaunos Therapeutics Inc range from $ to $
What's the earning quality score for Alaunos Therapeutics Inc?
Alaunos Therapeutics Inc has a earning quality score of B+/44.815712. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Alaunos Therapeutics Inc report earnings?
Alaunos Therapeutics Inc next earnings report is expected in 2026-06-29
What are Alaunos Therapeutics Inc's expected earnings?
Alaunos Therapeutics Inc expected earnings is $, according to wall-street analysts.
Did Alaunos Therapeutics Inc beat earnings expectations?
Alaunos Therapeutics Inc recent earnings of $ expectations.